Oligonucleotide therapeutics are entering a new phase of industry relevance. Once viewed as highly specialised tools for rare or genetically defined diseases, antisense oligonucleotides, siRNAs and other nucleic acid-based modalities are now central to broader therapeutic strategies across neurology, cardiovascular disease, metabolic disorders, oncology and beyond.

For senior leaders, the opportunity is significant. Oligonucleotide platforms offer the potential to reach targets that have historically sat beyond the limits of small molecules and biologics. They can be designed with speed, specificity and programmability, creating new routes to disease modification and portfolio differentiation.

However, as the field matures, so too does the risk landscape.

A recent article from the Oligonucleotide Therapeutics Society has highlighted emerging research on the impact of antisense oligonucleotides, or ASOs, on genome stability and DNA-repair enzyme activation. The article discusses findings from Hjelmgren and colleagues, published in Nature Communications, showing that phosphorothioate-modified ASOs can interact with key DNA-repair enzymes, including DNA-PKcs, ATM and PARP1. These interactions may lead to the formation of nuclear condensates that activate DNA-repair pathways, even in the absence of direct DNA damage.

The findings do not suggest that ASO therapeutics should be viewed as inherently unsafe. Instead, they reinforce a more strategic point: as oligonucleotide medicines move into larger pipelines, broader patient populations and more complex indications, safety evaluation must become more sophisticated, predictive and integrated earlier in development.

From technical promise to strategic responsibility

The rapid progress of oligonucleotide therapeutics has been driven by advances in chemistry, delivery, target selection and manufacturing. Chemical modifications such as phosphorothioate backbones have played a critical role in improving stability, tissue exposure and therapeutic feasibility. These innovations have helped transform ASOs from fragile research molecules into viable drug candidates.

Yet the same features that make these molecules therapeutically useful can also introduce complex biological interactions. The recent findings around DNA-repair enzyme activation are a reminder that oligonucleotides do not operate in isolation. Their behaviour is shaped by intracellular localisation, protein binding, tissue context, concentration, chemistry and duration of exposure.

For executives, this matters because it directly affects development risk, regulatory strategy and long-term portfolio value.

The key question is no longer simply whether an oligonucleotide can engage its intended target. The more important question is whether it can do so with a predictable therapeutic window, a robust safety profile and a translational package capable of supporting clinical, regulatory and commercial confidence.

Why genome stability should be on the leadership agenda

Genome stability is a foundational safety consideration. DNA-repair pathways are essential to cell health, and unintended activation or disruption of these systems can have implications for toxicity, tolerability and long-term risk management.

For leadership teams building oligonucleotide pipelines, the emerging science raises important strategic questions:

How early should DNA-damage response and genome-stability assessments be incorporated into candidate selection?

Are current screening cascades sufficient to detect unintended nuclear protein interactions?

How should organisations balance the proven advantages of established backbone chemistries with the need to minimise off-target biological effects?

What level of mechanistic understanding will regulators expect as the modality expands into broader indications?

How can companies avoid late-stage attrition by identifying safety liabilities earlier in discovery and preclinical development?

These questions are not theoretical. They influence investment decisions, platform strategy, partnering discussions, regulatory readiness and clinical development planning.

A more integrated model for oligonucleotide development

As oligonucleotide therapeutics mature, companies will need to move beyond siloed development models. The next generation of successful programmes will require closer alignment between discovery, toxicology, translational science, CMC, clinical pharmacology, regulatory affairs and commercial strategy.

Safety and developability can no longer be treated as downstream filters. They need to be designed into the molecule, the platform and the development plan from the outset.

This is particularly important because oligonucleotide therapeutics are not a single homogeneous class. A CNS-directed ASO, a hepatically targeted GalNAc-conjugated oligonucleotide and an oncology-focused nucleic acid therapy each present different delivery dynamics, exposure profiles, tissue risks and regulatory considerations. Development strategy must therefore be tailored to modality, indication and route of administration.

For senior executives, this creates both risk and opportunity. Organisations that can build more predictive, integrated development frameworks will be better positioned to reduce attrition, accelerate decision-making and strengthen confidence with investors, partners and regulators.

The commercial impact of better safety intelligence

The industry’s ability to convert oligonucleotide innovation into durable commercial value will depend on more than target novelty. It will depend on confidence.

Confidence that the molecule is differentiated.

Confidence that the safety profile is understood.

Confidence that manufacturing and quality systems can scale.

Confidence that regulators can evaluate the risk-benefit profile clearly.

Confidence that clinicians and patients can trust the therapy.

Emerging findings around ASOs and DNA-repair activation should therefore be viewed as part of a broader strategic shift. The companies that lead in this field will be those that use new mechanistic insights to refine their platforms, improve candidate selection and make smarter development decisions earlier.

Rather than slowing progress, this type of research can help the industry build stronger medicines, more resilient pipelines and more credible therapeutic platforms.

Continuing the conversation at ONP San Francisco

The strategic, scientific and operational questions facing the oligonucleotide and peptide therapeutics sector will be central to the Oligonucleotides & Peptides Xchange – San Francisco 2026, taking place on 3 September 2026.

This senior-level, invitation-only forum will bring together executives and scientific leaders from across pharma and biotech to discuss the challenges shaping the future of the field, including Novel Modalities & Discovery, Drug Delivery, CMC & Process Development, and Quality Control.

As oligonucleotide therapeutics continue to advance, the industry needs spaces where emerging science can be translated into practical development strategy. ONP San Francisco is designed to support exactly that: focused roundtable discussions, pre-arranged 1:1 meetings, expert-led sessions and structured networking with senior decision-makers working at the forefront of oligonucleotide and peptide innovation.

The recent findings on ASOs, genome stability and DNA-repair enzyme activation are not a reason to question the future of oligonucleotide therapeutics. They are a signal that the field is entering a more mature and strategically important stage.

For companies investing in this space, the next competitive advantage will not come from innovation alone. It will come from the ability to combine innovation with safety insight, regulatory foresight, manufacturing discipline and translational confidence.

To continue the discussion, join senior leaders from across the oligonucleotide and peptide therapeutics community: https://bit.ly/ONP-SF-2026

Bibliography

• Oligonucleotide Therapeutics Society. Interesting Findings on the Impact of Antisense Oligonucleotides on Genome Stability and DNA Repair Enzyme Activation
• Hjelmgren, A., et al. Nature Communications. Phosphorothioate antisense oligonucleotides disturb genome stability through aberrant activation of DNA repair enzymes
• Karolinska Institutet. Synthetic gene medicines may disrupt DNA repair
• U.S. Food & Drug Administration. Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics
• Signal Transduction and Targeted Therapy. Small nucleic acid drugs: approved medicines and future perspectives
• Frontiers in Pharmacology. Clinical pharmacology and drug–drug interaction considerations for RNA therapeutics
• hubXchange. Oligonucleotides & Peptides Xchange – San Francisco 2026